Idexx Laboratories (IDXX) 164.05 $IDXX
IDEXX Laboratories (IDXX) Showing Signs Of Being Strong And Under The Radar
at The Street - Thu Apr 23, 10:09AM CDT
Trade-Ideas LLC identified IDEXX Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 164.05 (+4.65)
Global Veterinary Diagnostics Market Analysis & Forecasts 2014-2020
M2 - Thu Apr 23, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d47b43/veterinary) has announced the addition of the "Veterinary Diagnostics Global Market Analysis - Forecast (2014-2020)" report to their offering. This report analyzes the global markets for Veterinary Diagnostics. The report provides the standard and the tailored research methodology approach. The market overview offers in depth analysis for the regional and country level analysis, for instance North America (U.S., and Canada), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2012 to 2020 for each given segments and sub segments. Market data derived from the authenticated and reliable sources subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, other activities. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Analysis 4 Porters Five Force Analysis 5 Veterinary Diagnostics Market by Product Type 5.1 Immunodiagnostics 5.2 Clinical Chemistry 5.3 Microbiology 5.4 Molecular Tests 5.5 Diagnostic Imaging 5.5.1 MRI 5.5.2 Ultrasound 5.5.3 Nuclear Imaging 5.5.4 Others 5.6 Hematology 5.7 Urinalysis 5.8 Others 6 Veterinary Diagnostics Market by Animal Type 6.1 Cattle 6.2 Poultry 6.3 Dogs 6.4 Cats 6.5 Horses 6.6 Swine 6.7 Others 7 Geographical Segmentation 8 Vendor Landscaping 9 Company Profiles - Abaxis - IDEXX Laboratories - Mindray Medical International Ltd. - Thermo Fisher Scientific Inc. - VCA - Zoetis For more information visit http://www.researchandmarkets.com/research/d47b43/veterinary
ABAX: 63.62 (+0.31), IDXX: 164.05 (+4.65), MR: 30.95 (+0.07)
BUYINS.NET: EME, GD, PH, JEC, IDXX, PDS Expected To Be Up Before Next Earnings Releases
M2 - Fri Apr 17, 6:58AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and April earnings reports. EMCOR Group Inc (NYSE:EME), General Dynamics Corp (NYSE:GD), PARKER-HANNIFIN CORPORATION (NYSE
H), Jacobs Engineering Group Inc (NYSE:JEC), IDEXX LABORATORIES INCORPORATED (NASDAQ:IDXX), PRECISION DRILLING CORP (NYSE DS) are all expected to be Up Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com . The following stocks are expected to go Up Before earnings are released Wednesday:
GD: 134.10 (+1.30), JEC: 46.31 (-0.85), PH: 122.49 (-0.94), PDS: 6.85 (-0.07), IDXX: 164.05 (+4.65), EME: 46.46 (-0.12)
The Growing Business Of Animal Healthcare
Value Line - Seeking Alpha - Tue Apr 14, 7:44AM CDT
By George M. Lee Despite an uneven economic recovery, demand for higher-quality animal healthcare continues to increase. Veterinary spending on pets has grown at a steady clip in recent years and ought to remain strong. Meanwhile many farmers...
VRX: 210.42 (+1.03), PAHC: 33.21 (unch), PFE: 35.27 (-0.09), WMT: 79.84 (+0.66), PDCO: 48.19 (+0.70), PETX: 15.86 (-0.43), LLY: 71.58 (-0.82), KIN: 7.33 (-0.19), ZTS: 47.91 (+0.86), ABC: 115.48 (+0.28), MWIV: 190.00 (+0.10), ABAX: 63.62 (+0.31), MRK: 57.60 (+0.09), ICCC: 6.31 (+0.06), TGT: 82.70 (+0.77), IDXX: 164.05 (+4.65), WOOF: 55.52 (-0.19), HSIC: 142.54 (+0.70), NVS: 104.28 (-1.22), PETM: 82.98 (+0.03)
IDEXX Laboratories to Release 2015 First Quarter Financial Results
PR Newswire - Wed Apr 08, 2:42PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2015 first quarter financial results for Tuesday, April 28, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
IDXX: 164.05 (+4.65)
Will Walgreens Boots (WBA) Earnings Disappoint in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 8:30AM CDT
Walgreens Boots Alliance is scheduled to report second-quarter fiscal 2015 results before the opening bell on Apr 9.
WBA: 85.98 (-0.71), OPK: 14.83 (+0.17), EW: 138.33 (-3.59), IDXX: 164.05 (+4.65)
BUYINS.NET: NSH, RSG, IDXX, PSI, EFG, WBMD Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Apr 07, 6:58AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Nustar GP Holdings LLC (NYSE:NSH), Searchgold Resources Inc (NYSE:RSG), IDEXX LABORATORIES INCORPORATED (NASDAQ:IDXX), Pason Systems Inc (NYSE SI), Ishares MSCI EAFE Growth Index Fund (NYSE:EFG), WebMD Health Corp (NASDAQ:WBMD) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
PSI: 26.49 (-0.68), WBMD: 46.89 (+0.64), RSG: 41.23 (+1.24), IDXX: 164.05 (+4.65), EFG: 73.45 (+0.38), NSH: 37.58 (-0.75)
IDEXX Banks on Strong CAG, Global Growth Continues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 3:15PM CDT
On Mar 31 2015, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
ABMD: 68.83 (-0.74), EW: 138.33 (-3.59), IDXX: 164.05 (+4.65), HOLX: 33.99 (+0.57)
Leading 100 Medical Devices Companies of USA/Canada 2015
M2 - Mon Mar 23, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9k2tjj/usacanada) has announced the addition of the "USA/Canada Medical Devices 100: An Industry Report" report to their offering. The United States is the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016 The U.S. market value represented about 38 percent of the global medical device market in 2012. The U.S. medical device companies are highly regarded globally for their innovations and high technology products. Canada's medical device market ranks as the ninth largest in the world. Canada has an estimated around $7 billion medical device market accounting for about 2 percent of the global market. The market is projected to increase at a CAGR of 4.0% to reach US$8.3bn by 2018. Around 80% of the market is supplied by imports, principally from the USA. With this special industry report, our endeavor is to provide the new investors with a complete resourceful research report for familiarizing with the present investment trends in USA/Canadian medical devices industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical devices companies of USA/Canada - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances with foreign companies - International presence of USA/Canadian medical devices companies - R&D activities in the industry Report Includes Companies Engaged in: - Manufacturing medical equipments/devices that have life span of more than one year and that can be used repeatedly on multiple patients or multiple medical tests can be done by using them - Manufacturing medical devices providing any medical activity and/or treatment - Manufacturing diagnostic devices - Manufacturing high-tech medical instruments - Manufacturing life-support medical devices Key Features: - Financial information compiled from reliable primary and secondary sources - Business news and transactions compiled from primary news sources, company websites, and press releases - Original news source links provided for each news for further reference - Senior colleagues who analyze news have years of experience Companies Mentioned (Partial List) - Harvard Bioscience, Inc. (United States) - Hasco Medical, Incorporation (United States) - Heartware International Inc (United States) - HEI Inc (United States) - Hill-Rom Holdings, Incorporation (United States) - Hologic, Inc. (United States) - IDEXX Laboratories Inc (United States) - Illumina, Inc. (United States) - Imris Incorporation (Canada) - Inogen Inc (United States) - Insulet Corporation (United States) - Integra LifeSciences Holdings Corporation (United States) - Invacare Corporation (United States) - IRIDEX Corporation (United States) - Lifeline Scientific, Inc (United States) - Lifeloc Technologies Inc (United States) - Medifocus Inc (Canada) For more information visit http://www.researchandmarkets.com/research/9k2tjj/usacanada
IRIX: 10.02 (+0.19), ILMN: 189.59 (-3.01), HBIO: 6.22 (+0.08), PODD: 30.72 (+0.11), IART: 61.31 (+0.84), IVC: 20.68 (+0.14), IMRS: 0.69 (+0.04), INGN: 37.13 (+0.11), IDXX: 164.05 (+4.65), HRC: 51.94 (+0.03), HOLX: 33.99 (+0.57)
World Market Report for Veterinary Diagnostics
M2 - Mon Mar 23, 7:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j3tp7c/the_world_market) has announced the addition of the "The World Market for Veterinary Diagnostics" report to their offering. International trade, public health, agricultural productivity, consumer confidence and companion animal-owner relationships are all dependent upon effective and increasingly specialized veterinary diagnostics products. In-vitro diagnostic (IVD) instrumentation and products have been extensively applied to veterinary healthcare; various assay forms, analytes and analyzers are transferrable from the clinical space to the veterinary clinic and laboratory. Major diagnostic methods in mainstream healthcare - immunodiagnostics, molecular testing (including nucleic acid testing), hematology and clinical chemistry - now have standard applications in the veterinary care of companion (pets) and food animals (livestock and production animals). The companion animal diagnostics market includes IVD products - instruments, consumables, test reagents and test kits - for the diagnosis of disease and health conditions in household pets (primarily dogs and cats) as well as horses. Market performance is determined by diagnostic product demand from veterinary clinics, hospitals, reference labs, and governmental and research laboratories such as those found at universities and associated with government agricultural and animal health authorities. Test products performed by pet owners - such as pet blood glucose meters and strips, pregnancy and ovulation tests, and urinalysis strips and cups - are also included in the companion animal diagnostics market. The primary segments of the global market for companion animal diagnostics include: - Clinical chemistry analyzer systems (instruments and consumables) - Infectious disease immunodiagnostics (reagents, assays and test kits) - Hematology analyzer systems (instruments and consumables for complete blood counts and differentials) - Other analyzer systems (immunoassay readers [instrument only], critical care and POC, coagulation, urinalysis analyzer systems and consumables) - Non-infectious disease immunodiagnostics (reagents, assays and test kits for endocrinal, digestive, autoimmune and other organ system conditions and disorders) - Molecular diagnostics (reagents, reagent kits, test kits) - Other testing (test-specific consumables primarily in histology and microbiology) The food animal diagnostics market includes primarily immunodiagnostic test kits, molecular test kits, reagents, other consumables, instruments and other supplies for disease diagnosis in livestock and production animals, commonly cattle, sheep, goats, rams, pigs, and poultry. The report scope also includes diagnostic testing on wildlife populations such as fowl, buffalo, deer, elk, moose and boar that are capable of transmitting diseases to human or food animal populations. The performance of the food animal diagnostics market is determined by the prevalence of infectious food animal diseases in a country or global region. Major product segments in food animal diagnostics include: - Immunodiagnostic test kits, reagents and other supplies - Molecular diagnostic test kits, reagents and other supplies (includes polymerase chain reaction [PCR], microarray, and genotyping kits) - Clinical chemistry, hematology, blood gas and electrolyte analysis (instruments and consumables) - Other infectious disease test reagents (microbiology cultures for characterization and identification, histology stains) The World Market for Veterinary Diagnostics also looks at the contextual market factors that have led to the more routine integration of diagnostics in companion animal care: - Correlation of volume of veterinary practice and animal hospital visits with in-clinic and reference lab testing activity - Consumer behavior and spending trends relating to companion animal ownership - Companion animal-owner relationships and the marketing efforts of the animal health industry - Development of the North American pet insurance market - Longer life expectancies for companion animals - The stability higher-income households inject into veterinary diagnostics demand Companies profiled in the report include: - Abaxis Corporation - Heska Corporation - IDEXX Laboratories Inc. - Life Technologies Corporation (Thermo Fisher) - Prionics AG (Thermo Fisher) - Zoetis - Other Market Participants For more information visit http://www.researchandmarkets.com/research/j3...rld_market
ABAX: 63.62 (+0.31), IDXX: 164.05 (+4.65)
Tracking The Sequoia Fund - Q4 2014
V is for Value - at Seeking Alpha - Thu Mar 12, 10:07AM CDT
WST: 57.38 (+0.78), VRX: 210.42 (+1.03), AAP: 148.61 (+1.92), CAB: 54.19 (-3.13), WMT: 79.84 (+0.66), CNQ: 33.62 (-0.01), DHR: 83.30 (-1.39), PCP: 200.51 (-4.65), GOOG: 565.06 (+18.06), FAST: 41.63 (-0.44), TRMB: 25.38 (-0.34), INT: 56.70 (-0.30), IBM: 169.78 (-0.46), COST: 148.12 (+0.82), GOOGL: 573.66 (+16.20), EME: 46.46 (-0.12), MA: 90.72 (-0.16), JEC: 46.31 (-0.85), ORLY: 229.35 (+1.04), TIF: 87.12 (+0.61), WAT: 123.54 (-0.81), ZTS: 47.91 (+0.86), OMC: 77.50 (-0.30), BRO: 32.43 (+0.16), VRSK: 72.68 (+0.20), GS: 197.99 (-1.32), TJX: 66.29 (-0.04), MHK: 179.26 (+0.72), EXPD: 46.46 (-0.21), RBA: 25.27 (+0.25), IDXX: 164.05 (+4.65), PX: 122.46 (+0.60), BRK.B: 142.09 (-0.34), BRK.A: 214,490.00 (-250.00)
Look for Shares of Idexx Laboratories to Potentially Rebound after Yesterday's 1.37% Sell Off
Comtex SmarTrend(R) - Mon Mar 09, 5:36PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $152.02 to a high of $154.31. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $153.90 on volume of 449,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IDXX: 164.05 (+4.65)
Cramer's Four Horsemen - Cramer's Lightning Round (3/3/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Wed Mar 04, 5:03AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, March 3. Bullish Calls: Idexx Labs (NASDAQ: IDXX ): "We love those guys. It quietly goes higher and higher." FireEye (NASDAQ: FEYE ): "I...
DISCK: 31.02 (-0.78), FEYE: 44.03 (+0.10), CYBR: 66.78 (+0.16), WWE: 14.48 (-0.18), DISCB: 33.42 (-0.27), DISCA: 32.71 (-0.93), KKR: 23.39 (-0.15), IDXX: 164.05 (+4.65), FTNT: 38.68 (-0.04), PANW: 153.84 (-0.94)
'Mad Money' Lightning Round: World Wrestling Entertainment Isn't for Me
at The Street - Wed Mar 04, 5:00AM CST
Cramer loves Idexx Laboratories, is sticking with Kohlberg Kravis Roberts and is a fan of FireEye.
BX: 41.41 (+0.42), WWE: 14.48 (-0.18), CYBR: 66.78 (+0.16), KKR: 23.39 (-0.15), IDXX: 164.05 (+4.65), PANW: 153.84 (-0.94), FTNT: 38.68 (-0.04)
Jim Cramer's 'Mad Money' Recap: Fear and Skepticism Are Good
at The Street - Tue Mar 03, 7:16PM CST
Investors took off their rose-colored glasses from yesterday's session and returned to focusing on the negatives, Cramer says.
BX: 41.41 (+0.42), WWE: 14.48 (-0.18), CYBR: 66.78 (+0.16), BBY: 35.39 (-0.74), KKR: 23.39 (-0.15), PANW: 153.84 (-0.94), DIN: 103.05 (+1.95), AZO: 702.00 (-0.33), TRUE: 15.62 (-0.09), IDXX: 164.05 (+4.65), FTNT: 38.68 (-0.04)
Digital Pathology Systems - Global Strategic Business Report 2015-2020: Fast Paced Adoption in Cancer and Other Chronic Diseases
M2 - Thu Feb 12, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/vdhg3v/digital_pathology) has announced the addition of the "Digital Pathology Systems - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Digital Pathology Systems in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 50 companies including many key and niche players such as: - 3DHISTECH Ltd. - AccelPath, Inc. - Apollo PACS, Inc. - Carl Zeiss AG - Corista LLC - Definiens AG - DigiPath Inc. - Flagship Biosciences, LLC - Koninklijke Philips Electronics N.V. - Leica Microsystems GmbH - MikroScan Technologies, Inc. - Olympus America, Inc. - Omnyx, LLC - Pixcelldata Ltd. - Ventana Medical Systems, Inc. - VMscope GmbH Key Topics Covered: 1. INDUSTRY OVERVIEW - A Prelude - Impact of Economic Recession in Retrospect & the Road Ahead - Market Outlook - Developed Markets to Maintain their Dominance - Digital Pathology Systems See Fast Paced Growth in Emerging Nations - Analytics: A Fast Growing Segment - Key Issues Hampering the Wider Adoption of Digital Pathology Systems - The Future in Retrospect 2. MARKET DRIVERS, TRENDS & ISSUES - The Need for Automation in Tissue Analysis - Workflow Efficiencies: A Key Market Driver for Digital Pathology Systems - Scarcity of Pathologists & Excess Workload on Pathology Labs Drives Demand for Digital Systems - Need for Early Diagnosis Puts Focus on Digital Pathology - Clinical Research Continues to be Core Vertical for Digital Pathology - Technological Advances Ease Issues in Digital Pathology Adoption - Possibilities Ahead in Digital Pathology - Digital Pathology Systems Continue to Widen their Scope - Digital Pathology Systems See Fast Paced Adoption in Cancer and Other Chronic Diseases - Move towards Hosted Technology: The New Fad - Digital Pathology as a Service Eludes Cost-based Issues - Telepathology Expected to Pave Way for Pathology Outsourcing to Developing Nations - Rising Emphasis on Lab Automation Extends Opportunity for Digital Pathology - Rising Penetration of Personalized Medicine Bodes Well for Digital Pathology - Increased Focus on Companion Diagnostics to Benefit the Market - Improving Healthcare & Research Expenditures Turbo Charge Digital Pathology - Burgeoning Global Population: A Strong Business Case for Market Growth - Aging Population: A Key Opportunity Indicator - Key Issues Hampering the Wider Adoption of Digital Pathology Systems - High Costs - Workflow Integration with Other Related Functions - Other Issues 3. COMPETITION - Leica Dominates the Market - Consolidation Rife in the Digital Pathology Space 4. PRODUCT OVERVIEW - An Introduction to Pathology - Digital Pathology: Computer-Enabled Pathology Process - Digital Pathology System: Components - Slide Scanners - Analytics - Storage - Communication - Applications - Remote Reviewing - Digital-Assisted Mathematical Analysis - Data Storage - Telepathology - Static Telepathology - Dynamic Telepathology - Hybrid Telepathology - Bio-banking - Multinational Integration - Tissue Microarray Analysis - A Review of Information Archival and Retrieval in Digital Pathology - Storage and Interoperability - Location and Internal Communication - Systems and Data Reliability - Image Life-Cycle Management - IT infrastructure and Management Costs - Factors Affecting Information Archival - Digital Pathology Management Systems - Benefits of Digital Pathology Systems - Easier Analysis and Archival & Retrieval of Digital Images - Access to Digital Slide Images Anytime Anywhere 5. PRODUCT INTRODUCTIONS/INNOVATIONS - Philips Obtains CE Mark Approval for Diagnostic Use of its Philips Digital Pathology Solution - Mikroscan Technologies Unveils Mikroscan L6 and the Mikroscan MC2 Telepathology Systems - Royal Philips Receives FDA 510(k) Clearance for Her2/neu IHC Digital Manual Read Product - Ventana Medical Systems Launches iScan HT Slide Scanner - Ventana Obtains FDA 510(k) Clearance for VENTANA Companion Algorithm Ki-67 (30-9) Image Analysis Solution 6. RECENT INDUSTRY ACTIVITY - Visiopharm Begins Operations in Benelux - Pixcelldata Selects Edge Solutions as its US Partner - CellNetix Pathology and Laboratories Merges with Highline Pathology Associates - Definiens Teams Up with Clarient Diagnostic Services - Pixcelldata Signs Partnership Deal with eX-Path - Pixcelldata Inks Partnership Agreement with Basys Data - IDEXX Laboratories Inks Collaboration Agreement with Royal Philips - Ventana Medical Systems and EMC Join Hands - XIFIN Acquires PathCentral - Kanteron Systems Signs Joint Selling & Marketing Agreement with DigiPath - DigiPath Inks New Agreement with Personalized Diagnostic - Dako to Launch Clinical Image Analysis for Digital Pathology - Ventana Medical Systems Inks Global Agreement with Barco - MEDITE Teams Up with UNIC Technologies - Leica Biosystems Takes Over Aperio Technologies - Carl Zeiss MicroImaging and Olympus America Sign Licensing Agreement - Aperio Technologies and Dell Enter into Strategic Collaboration - AccelPath Acquires DigiPath Solutions - Leica Microsystems and Indica Labs Sign Agreement - Omnyx Receives CE Mark in Europe - Erasmus MC Selects Philips to Adopt Digital Pathology System 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 50 (including Divisions/Subsidiaries 54) - The United States (27) - Canada (4) - Japan (2) - Europe (19) - Germany (6) - The United Kingdom (1) - Spain (1) - Rest of Europe (11) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/vd..._pathology
PHG: 29.67 (+0.17), IDXX: 164.05 (+4.65)
Idexx Labs (IDXX) Downgraded From Buy to Hold
at The Street - Tue Feb 03, 11:20AM CST
Idexx Labs (IDXX) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
IDXX: 164.05 (+4.65)
Shares of IDXX Up 27.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 03, 11:14AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 4 months, Idexx Laboratories has returned 27.23% as of today's recent price of $155.87.
IDXX: 164.05 (+4.65)
IDEXX Tops Q4 Earnings, Lags Revenues; Tweaks 2015 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:25AM CST
IDEXX Laboratories, Inc. (IDXX), reported adjusted earnings per share (EPS) of 95 cents in the fourth quarter of 2014.
HNSN: 0.89 (-0.03), EW: 138.33 (-3.59), IDXX: 164.05 (+4.65), HOLX: 33.99 (+0.57)
IDEXX Laboratories' (IDXX) CEO Jon Ayers on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Jan 30, 6:44PM CST
IDXX: 164.05 (+4.65)
IDEXX Laboratories (IDXX) Showing Signs Of Being Strong And Under The Radar
at The Street - Thu Apr 23, 10:09AM CDT
Trade-Ideas LLC identified IDEXX Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 164.05 (+4.65)
Global Veterinary Diagnostics Market Analysis & Forecasts 2014-2020
M2 - Thu Apr 23, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d47b43/veterinary) has announced the addition of the "Veterinary Diagnostics Global Market Analysis - Forecast (2014-2020)" report to their offering. This report analyzes the global markets for Veterinary Diagnostics. The report provides the standard and the tailored research methodology approach. The market overview offers in depth analysis for the regional and country level analysis, for instance North America (U.S., and Canada), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2012 to 2020 for each given segments and sub segments. Market data derived from the authenticated and reliable sources subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, other activities. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Analysis 4 Porters Five Force Analysis 5 Veterinary Diagnostics Market by Product Type 5.1 Immunodiagnostics 5.2 Clinical Chemistry 5.3 Microbiology 5.4 Molecular Tests 5.5 Diagnostic Imaging 5.5.1 MRI 5.5.2 Ultrasound 5.5.3 Nuclear Imaging 5.5.4 Others 5.6 Hematology 5.7 Urinalysis 5.8 Others 6 Veterinary Diagnostics Market by Animal Type 6.1 Cattle 6.2 Poultry 6.3 Dogs 6.4 Cats 6.5 Horses 6.6 Swine 6.7 Others 7 Geographical Segmentation 8 Vendor Landscaping 9 Company Profiles - Abaxis - IDEXX Laboratories - Mindray Medical International Ltd. - Thermo Fisher Scientific Inc. - VCA - Zoetis For more information visit http://www.researchandmarkets.com/research/d47b43/veterinary
ABAX: 63.62 (+0.31), IDXX: 164.05 (+4.65), MR: 30.95 (+0.07)
BUYINS.NET: EME, GD, PH, JEC, IDXX, PDS Expected To Be Up Before Next Earnings Releases
M2 - Fri Apr 17, 6:58AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and April earnings reports. EMCOR Group Inc (NYSE:EME), General Dynamics Corp (NYSE:GD), PARKER-HANNIFIN CORPORATION (NYSE
H), Jacobs Engineering Group Inc (NYSE:JEC), IDEXX LABORATORIES INCORPORATED (NASDAQ:IDXX), PRECISION DRILLING CORP (NYSE DS) are all expected to be Up Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com . The following stocks are expected to go Up Before earnings are released Wednesday: GD: 134.10 (+1.30), JEC: 46.31 (-0.85), PH: 122.49 (-0.94), PDS: 6.85 (-0.07), IDXX: 164.05 (+4.65), EME: 46.46 (-0.12)
The Growing Business Of Animal Healthcare
Value Line - Seeking Alpha - Tue Apr 14, 7:44AM CDT
By George M. Lee Despite an uneven economic recovery, demand for higher-quality animal healthcare continues to increase. Veterinary spending on pets has grown at a steady clip in recent years and ought to remain strong. Meanwhile many farmers...
VRX: 210.42 (+1.03), PAHC: 33.21 (unch), PFE: 35.27 (-0.09), WMT: 79.84 (+0.66), PDCO: 48.19 (+0.70), PETX: 15.86 (-0.43), LLY: 71.58 (-0.82), KIN: 7.33 (-0.19), ZTS: 47.91 (+0.86), ABC: 115.48 (+0.28), MWIV: 190.00 (+0.10), ABAX: 63.62 (+0.31), MRK: 57.60 (+0.09), ICCC: 6.31 (+0.06), TGT: 82.70 (+0.77), IDXX: 164.05 (+4.65), WOOF: 55.52 (-0.19), HSIC: 142.54 (+0.70), NVS: 104.28 (-1.22), PETM: 82.98 (+0.03)
IDEXX Laboratories to Release 2015 First Quarter Financial Results
PR Newswire - Wed Apr 08, 2:42PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2015 first quarter financial results for Tuesday, April 28, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
IDXX: 164.05 (+4.65)
Will Walgreens Boots (WBA) Earnings Disappoint in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 8:30AM CDT
Walgreens Boots Alliance is scheduled to report second-quarter fiscal 2015 results before the opening bell on Apr 9.
WBA: 85.98 (-0.71), OPK: 14.83 (+0.17), EW: 138.33 (-3.59), IDXX: 164.05 (+4.65)
BUYINS.NET: NSH, RSG, IDXX, PSI, EFG, WBMD Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Apr 07, 6:58AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Nustar GP Holdings LLC (NYSE:NSH), Searchgold Resources Inc (NYSE:RSG), IDEXX LABORATORIES INCORPORATED (NASDAQ:IDXX), Pason Systems Inc (NYSE
SI), Ishares MSCI EAFE Growth Index Fund (NYSE:EFG), WebMD Health Corp (NASDAQ:WBMD) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: PSI: 26.49 (-0.68), WBMD: 46.89 (+0.64), RSG: 41.23 (+1.24), IDXX: 164.05 (+4.65), EFG: 73.45 (+0.38), NSH: 37.58 (-0.75)
IDEXX Banks on Strong CAG, Global Growth Continues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 3:15PM CDT
On Mar 31 2015, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
ABMD: 68.83 (-0.74), EW: 138.33 (-3.59), IDXX: 164.05 (+4.65), HOLX: 33.99 (+0.57)
Leading 100 Medical Devices Companies of USA/Canada 2015
M2 - Mon Mar 23, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9k2tjj/usacanada) has announced the addition of the "USA/Canada Medical Devices 100: An Industry Report" report to their offering. The United States is the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016 The U.S. market value represented about 38 percent of the global medical device market in 2012. The U.S. medical device companies are highly regarded globally for their innovations and high technology products. Canada's medical device market ranks as the ninth largest in the world. Canada has an estimated around $7 billion medical device market accounting for about 2 percent of the global market. The market is projected to increase at a CAGR of 4.0% to reach US$8.3bn by 2018. Around 80% of the market is supplied by imports, principally from the USA. With this special industry report, our endeavor is to provide the new investors with a complete resourceful research report for familiarizing with the present investment trends in USA/Canadian medical devices industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical devices companies of USA/Canada - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances with foreign companies - International presence of USA/Canadian medical devices companies - R&D activities in the industry Report Includes Companies Engaged in: - Manufacturing medical equipments/devices that have life span of more than one year and that can be used repeatedly on multiple patients or multiple medical tests can be done by using them - Manufacturing medical devices providing any medical activity and/or treatment - Manufacturing diagnostic devices - Manufacturing high-tech medical instruments - Manufacturing life-support medical devices Key Features: - Financial information compiled from reliable primary and secondary sources - Business news and transactions compiled from primary news sources, company websites, and press releases - Original news source links provided for each news for further reference - Senior colleagues who analyze news have years of experience Companies Mentioned (Partial List) - Harvard Bioscience, Inc. (United States) - Hasco Medical, Incorporation (United States) - Heartware International Inc (United States) - HEI Inc (United States) - Hill-Rom Holdings, Incorporation (United States) - Hologic, Inc. (United States) - IDEXX Laboratories Inc (United States) - Illumina, Inc. (United States) - Imris Incorporation (Canada) - Inogen Inc (United States) - Insulet Corporation (United States) - Integra LifeSciences Holdings Corporation (United States) - Invacare Corporation (United States) - IRIDEX Corporation (United States) - Lifeline Scientific, Inc (United States) - Lifeloc Technologies Inc (United States) - Medifocus Inc (Canada) For more information visit http://www.researchandmarkets.com/research/9k2tjj/usacanada
IRIX: 10.02 (+0.19), ILMN: 189.59 (-3.01), HBIO: 6.22 (+0.08), PODD: 30.72 (+0.11), IART: 61.31 (+0.84), IVC: 20.68 (+0.14), IMRS: 0.69 (+0.04), INGN: 37.13 (+0.11), IDXX: 164.05 (+4.65), HRC: 51.94 (+0.03), HOLX: 33.99 (+0.57)
World Market Report for Veterinary Diagnostics
M2 - Mon Mar 23, 7:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j3tp7c/the_world_market) has announced the addition of the "The World Market for Veterinary Diagnostics" report to their offering. International trade, public health, agricultural productivity, consumer confidence and companion animal-owner relationships are all dependent upon effective and increasingly specialized veterinary diagnostics products. In-vitro diagnostic (IVD) instrumentation and products have been extensively applied to veterinary healthcare; various assay forms, analytes and analyzers are transferrable from the clinical space to the veterinary clinic and laboratory. Major diagnostic methods in mainstream healthcare - immunodiagnostics, molecular testing (including nucleic acid testing), hematology and clinical chemistry - now have standard applications in the veterinary care of companion (pets) and food animals (livestock and production animals). The companion animal diagnostics market includes IVD products - instruments, consumables, test reagents and test kits - for the diagnosis of disease and health conditions in household pets (primarily dogs and cats) as well as horses. Market performance is determined by diagnostic product demand from veterinary clinics, hospitals, reference labs, and governmental and research laboratories such as those found at universities and associated with government agricultural and animal health authorities. Test products performed by pet owners - such as pet blood glucose meters and strips, pregnancy and ovulation tests, and urinalysis strips and cups - are also included in the companion animal diagnostics market. The primary segments of the global market for companion animal diagnostics include: - Clinical chemistry analyzer systems (instruments and consumables) - Infectious disease immunodiagnostics (reagents, assays and test kits) - Hematology analyzer systems (instruments and consumables for complete blood counts and differentials) - Other analyzer systems (immunoassay readers [instrument only], critical care and POC, coagulation, urinalysis analyzer systems and consumables) - Non-infectious disease immunodiagnostics (reagents, assays and test kits for endocrinal, digestive, autoimmune and other organ system conditions and disorders) - Molecular diagnostics (reagents, reagent kits, test kits) - Other testing (test-specific consumables primarily in histology and microbiology) The food animal diagnostics market includes primarily immunodiagnostic test kits, molecular test kits, reagents, other consumables, instruments and other supplies for disease diagnosis in livestock and production animals, commonly cattle, sheep, goats, rams, pigs, and poultry. The report scope also includes diagnostic testing on wildlife populations such as fowl, buffalo, deer, elk, moose and boar that are capable of transmitting diseases to human or food animal populations. The performance of the food animal diagnostics market is determined by the prevalence of infectious food animal diseases in a country or global region. Major product segments in food animal diagnostics include: - Immunodiagnostic test kits, reagents and other supplies - Molecular diagnostic test kits, reagents and other supplies (includes polymerase chain reaction [PCR], microarray, and genotyping kits) - Clinical chemistry, hematology, blood gas and electrolyte analysis (instruments and consumables) - Other infectious disease test reagents (microbiology cultures for characterization and identification, histology stains) The World Market for Veterinary Diagnostics also looks at the contextual market factors that have led to the more routine integration of diagnostics in companion animal care: - Correlation of volume of veterinary practice and animal hospital visits with in-clinic and reference lab testing activity - Consumer behavior and spending trends relating to companion animal ownership - Companion animal-owner relationships and the marketing efforts of the animal health industry - Development of the North American pet insurance market - Longer life expectancies for companion animals - The stability higher-income households inject into veterinary diagnostics demand Companies profiled in the report include: - Abaxis Corporation - Heska Corporation - IDEXX Laboratories Inc. - Life Technologies Corporation (Thermo Fisher) - Prionics AG (Thermo Fisher) - Zoetis - Other Market Participants For more information visit http://www.researchandmarkets.com/research/j3...rld_market
ABAX: 63.62 (+0.31), IDXX: 164.05 (+4.65)
Tracking The Sequoia Fund - Q4 2014
V is for Value - at Seeking Alpha - Thu Mar 12, 10:07AM CDT
WST: 57.38 (+0.78), VRX: 210.42 (+1.03), AAP: 148.61 (+1.92), CAB: 54.19 (-3.13), WMT: 79.84 (+0.66), CNQ: 33.62 (-0.01), DHR: 83.30 (-1.39), PCP: 200.51 (-4.65), GOOG: 565.06 (+18.06), FAST: 41.63 (-0.44), TRMB: 25.38 (-0.34), INT: 56.70 (-0.30), IBM: 169.78 (-0.46), COST: 148.12 (+0.82), GOOGL: 573.66 (+16.20), EME: 46.46 (-0.12), MA: 90.72 (-0.16), JEC: 46.31 (-0.85), ORLY: 229.35 (+1.04), TIF: 87.12 (+0.61), WAT: 123.54 (-0.81), ZTS: 47.91 (+0.86), OMC: 77.50 (-0.30), BRO: 32.43 (+0.16), VRSK: 72.68 (+0.20), GS: 197.99 (-1.32), TJX: 66.29 (-0.04), MHK: 179.26 (+0.72), EXPD: 46.46 (-0.21), RBA: 25.27 (+0.25), IDXX: 164.05 (+4.65), PX: 122.46 (+0.60), BRK.B: 142.09 (-0.34), BRK.A: 214,490.00 (-250.00)
Look for Shares of Idexx Laboratories to Potentially Rebound after Yesterday's 1.37% Sell Off
Comtex SmarTrend(R) - Mon Mar 09, 5:36PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $152.02 to a high of $154.31. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $153.90 on volume of 449,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IDXX: 164.05 (+4.65)
Cramer's Four Horsemen - Cramer's Lightning Round (3/3/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Wed Mar 04, 5:03AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, March 3. Bullish Calls: Idexx Labs (NASDAQ: IDXX ): "We love those guys. It quietly goes higher and higher." FireEye (NASDAQ: FEYE ): "I...
DISCK: 31.02 (-0.78), FEYE: 44.03 (+0.10), CYBR: 66.78 (+0.16), WWE: 14.48 (-0.18), DISCB: 33.42 (-0.27), DISCA: 32.71 (-0.93), KKR: 23.39 (-0.15), IDXX: 164.05 (+4.65), FTNT: 38.68 (-0.04), PANW: 153.84 (-0.94)
'Mad Money' Lightning Round: World Wrestling Entertainment Isn't for Me
at The Street - Wed Mar 04, 5:00AM CST
Cramer loves Idexx Laboratories, is sticking with Kohlberg Kravis Roberts and is a fan of FireEye.
BX: 41.41 (+0.42), WWE: 14.48 (-0.18), CYBR: 66.78 (+0.16), KKR: 23.39 (-0.15), IDXX: 164.05 (+4.65), PANW: 153.84 (-0.94), FTNT: 38.68 (-0.04)
Jim Cramer's 'Mad Money' Recap: Fear and Skepticism Are Good
at The Street - Tue Mar 03, 7:16PM CST
Investors took off their rose-colored glasses from yesterday's session and returned to focusing on the negatives, Cramer says.
BX: 41.41 (+0.42), WWE: 14.48 (-0.18), CYBR: 66.78 (+0.16), BBY: 35.39 (-0.74), KKR: 23.39 (-0.15), PANW: 153.84 (-0.94), DIN: 103.05 (+1.95), AZO: 702.00 (-0.33), TRUE: 15.62 (-0.09), IDXX: 164.05 (+4.65), FTNT: 38.68 (-0.04)
Digital Pathology Systems - Global Strategic Business Report 2015-2020: Fast Paced Adoption in Cancer and Other Chronic Diseases
M2 - Thu Feb 12, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/vdhg3v/digital_pathology) has announced the addition of the "Digital Pathology Systems - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Digital Pathology Systems in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report profiles 50 companies including many key and niche players such as: - 3DHISTECH Ltd. - AccelPath, Inc. - Apollo PACS, Inc. - Carl Zeiss AG - Corista LLC - Definiens AG - DigiPath Inc. - Flagship Biosciences, LLC - Koninklijke Philips Electronics N.V. - Leica Microsystems GmbH - MikroScan Technologies, Inc. - Olympus America, Inc. - Omnyx, LLC - Pixcelldata Ltd. - Ventana Medical Systems, Inc. - VMscope GmbH Key Topics Covered: 1. INDUSTRY OVERVIEW - A Prelude - Impact of Economic Recession in Retrospect & the Road Ahead - Market Outlook - Developed Markets to Maintain their Dominance - Digital Pathology Systems See Fast Paced Growth in Emerging Nations - Analytics: A Fast Growing Segment - Key Issues Hampering the Wider Adoption of Digital Pathology Systems - The Future in Retrospect 2. MARKET DRIVERS, TRENDS & ISSUES - The Need for Automation in Tissue Analysis - Workflow Efficiencies: A Key Market Driver for Digital Pathology Systems - Scarcity of Pathologists & Excess Workload on Pathology Labs Drives Demand for Digital Systems - Need for Early Diagnosis Puts Focus on Digital Pathology - Clinical Research Continues to be Core Vertical for Digital Pathology - Technological Advances Ease Issues in Digital Pathology Adoption - Possibilities Ahead in Digital Pathology - Digital Pathology Systems Continue to Widen their Scope - Digital Pathology Systems See Fast Paced Adoption in Cancer and Other Chronic Diseases - Move towards Hosted Technology: The New Fad - Digital Pathology as a Service Eludes Cost-based Issues - Telepathology Expected to Pave Way for Pathology Outsourcing to Developing Nations - Rising Emphasis on Lab Automation Extends Opportunity for Digital Pathology - Rising Penetration of Personalized Medicine Bodes Well for Digital Pathology - Increased Focus on Companion Diagnostics to Benefit the Market - Improving Healthcare & Research Expenditures Turbo Charge Digital Pathology - Burgeoning Global Population: A Strong Business Case for Market Growth - Aging Population: A Key Opportunity Indicator - Key Issues Hampering the Wider Adoption of Digital Pathology Systems - High Costs - Workflow Integration with Other Related Functions - Other Issues 3. COMPETITION - Leica Dominates the Market - Consolidation Rife in the Digital Pathology Space 4. PRODUCT OVERVIEW - An Introduction to Pathology - Digital Pathology: Computer-Enabled Pathology Process - Digital Pathology System: Components - Slide Scanners - Analytics - Storage - Communication - Applications - Remote Reviewing - Digital-Assisted Mathematical Analysis - Data Storage - Telepathology - Static Telepathology - Dynamic Telepathology - Hybrid Telepathology - Bio-banking - Multinational Integration - Tissue Microarray Analysis - A Review of Information Archival and Retrieval in Digital Pathology - Storage and Interoperability - Location and Internal Communication - Systems and Data Reliability - Image Life-Cycle Management - IT infrastructure and Management Costs - Factors Affecting Information Archival - Digital Pathology Management Systems - Benefits of Digital Pathology Systems - Easier Analysis and Archival & Retrieval of Digital Images - Access to Digital Slide Images Anytime Anywhere 5. PRODUCT INTRODUCTIONS/INNOVATIONS - Philips Obtains CE Mark Approval for Diagnostic Use of its Philips Digital Pathology Solution - Mikroscan Technologies Unveils Mikroscan L6 and the Mikroscan MC2 Telepathology Systems - Royal Philips Receives FDA 510(k) Clearance for Her2/neu IHC Digital Manual Read Product - Ventana Medical Systems Launches iScan HT Slide Scanner - Ventana Obtains FDA 510(k) Clearance for VENTANA Companion Algorithm Ki-67 (30-9) Image Analysis Solution 6. RECENT INDUSTRY ACTIVITY - Visiopharm Begins Operations in Benelux - Pixcelldata Selects Edge Solutions as its US Partner - CellNetix Pathology and Laboratories Merges with Highline Pathology Associates - Definiens Teams Up with Clarient Diagnostic Services - Pixcelldata Signs Partnership Deal with eX-Path - Pixcelldata Inks Partnership Agreement with Basys Data - IDEXX Laboratories Inks Collaboration Agreement with Royal Philips - Ventana Medical Systems and EMC Join Hands - XIFIN Acquires PathCentral - Kanteron Systems Signs Joint Selling & Marketing Agreement with DigiPath - DigiPath Inks New Agreement with Personalized Diagnostic - Dako to Launch Clinical Image Analysis for Digital Pathology - Ventana Medical Systems Inks Global Agreement with Barco - MEDITE Teams Up with UNIC Technologies - Leica Biosystems Takes Over Aperio Technologies - Carl Zeiss MicroImaging and Olympus America Sign Licensing Agreement - Aperio Technologies and Dell Enter into Strategic Collaboration - AccelPath Acquires DigiPath Solutions - Leica Microsystems and Indica Labs Sign Agreement - Omnyx Receives CE Mark in Europe - Erasmus MC Selects Philips to Adopt Digital Pathology System 7. FOCUS ON SELECT GLOBAL PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 50 (including Divisions/Subsidiaries 54) - The United States (27) - Canada (4) - Japan (2) - Europe (19) - Germany (6) - The United Kingdom (1) - Spain (1) - Rest of Europe (11) - Asia-Pacific (Excluding Japan) (2) For more information visit http://www.researchandmarkets.com/research/vd..._pathology
PHG: 29.67 (+0.17), IDXX: 164.05 (+4.65)
Idexx Labs (IDXX) Downgraded From Buy to Hold
at The Street - Tue Feb 03, 11:20AM CST
Idexx Labs (IDXX) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
IDXX: 164.05 (+4.65)
Shares of IDXX Up 27.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 03, 11:14AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 4 months, Idexx Laboratories has returned 27.23% as of today's recent price of $155.87.
IDXX: 164.05 (+4.65)
IDEXX Tops Q4 Earnings, Lags Revenues; Tweaks 2015 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:25AM CST
IDEXX Laboratories, Inc. (IDXX), reported adjusted earnings per share (EPS) of 95 cents in the fourth quarter of 2014.
HNSN: 0.89 (-0.03), EW: 138.33 (-3.59), IDXX: 164.05 (+4.65), HOLX: 33.99 (+0.57)
IDEXX Laboratories' (IDXX) CEO Jon Ayers on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Jan 30, 6:44PM CST
IDXX: 164.05 (+4.65)
